COMPANY PROFILE

Enterome

A clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases

Paris, FranceFounded 2011Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Enterome

Enterome is a clinical-stage company that is developing innovative cancer treatments. The company operates in the healthcare sector, specifically in the field of oncology. Its primary clients are patients suffering from various types of cancer, including recurrent glioblastoma and Non-Hodgkin lymphoma.

The company's business model revolves around the development and commercialization of its proprietary OncoMimics™ technology. This technology stimulates a patient's own immune system to fight cancer, overcoming the body's natural tolerance to self-antigens. In simpler terms, it trains the body's immune cells to recognize and attack cancer cells.

Enterome's most advanced programs, EO2401 and EO2463, are currently in Phase 2 clinical trials. These trials have shown promising results in terms of efficacy and safety in over 180 patients. The company's research and development platform has the potential to deliver multiple candidates for cancer treatment, with a rapid progression from laboratory research to patient treatment.

In addition to its cancer treatments, Enterome has also established a partnership with Nestlé Health Science to develop treatments for inflammatory diseases and food allergies. This diversification of its product portfolio allows Enterome to tap into different segments of the healthcare market.

Enterome generates revenue through the development and commercialization of its treatments. The company also stands to earn income from its partnership with Nestlé Health Science.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Paris, France
Employees: 33
Open positions: None listed
Dealroom signal: 63.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Inflammatory Diseases, Microbiology, Spinout, Biotech and Pharma, Woman Founder, Horizon Europe, radar de l'innovation, observatoire industrial tech, DT and LS
Business model: Manufacturing
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2025	$9.6M	$255M	Primo Capital · Seventure Partners · The Leukemia & Lymphoma Society · Lundbeckfonden	↗
GRANTOther financing	Jun 2025	$8.6M	—	The Institute for Follicular Lymphoma Innovation	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Enterome website traffic

Latest recorded traffic for Enterome is 4K monthly website visits, up 53.8% over the last three months. Enterome's team declined 8.3% over the past year.

Latest monthly visits4K 3-month web change+53.8% 1-year team growth-8.3%

Monthly website visitsOct 2014–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NPNETRIS PharmaMonoclonal antibodies overcoming cancer therapy resistance.	Lyon, France	Operational	20	$20M	$33M
DMDamae MedicalMedical device capable of seeing biological tissues in depth, at a cellular level and in vivo	Paris, France	Operational
SISmart ImmuneDevelops off-the-shelf allogeneic T-cell progenitor therapies to restore a fully functional immune system in patients with cancer and severe infections	Paris, France	Operational
CICilcareAdvanced solutions for drug in hearing and ear disorders	Montpellier, France	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational